Novartis’s Cosentyx failed to beat a placebo in a Phase 3 clinical trial in giant cell arteritis. The antibody drug was being developed as an alternative to Roche and AbbVie drugs whose approved uses include treating this autoimmune disorder affecting blood vessels.
The post Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use to Rare Blood Vessel Disorder appeared first on MedCity News.
